MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline.

Monopar Therapeutics stock remains centered on its development-stage pipeline and Nasdaq listing. The company is a small-cap biotech with no live catalyst available in the search results.

By Christina Vaughn, Background & Management desk. Reviewed on July 7, 2026 at 5:01 p.m. ET.

Monopar Therapeutics Inc. (US6093601054) is a clinical-stage biotechnology company listed on Nasdaq under the ticker MNPR. Its business centers on developing therapies for oncology and rare diseases, a model that leaves the stock closely tied to trial progress, financing decisions and regulatory milestones.

Pipeline first

The company's lead programs have historically been the main driver of investor attention, because valuation in development-stage biotech depends heavily on data, timing and capital access. For U.S. investors, that makes the Nasdaq listing and the SEC filing trail the most relevant public reference points.

How the business works

Monopar does not sell a broad portfolio of commercial drugs. Instead, it advances a small number of drug candidates through research and development, which means each update can matter more than in a mature pharmaceutical group.

Lead program

One representative example is ALXN1840, an investigational copper-binding therapy that the company has studied in Wilson disease. That kind of asset illustrates the company's model: a focused pipeline, limited commercial diversification and a valuation that can shift with clinical evidence.

Stock context

As of July 7, 2026, Monopar Therapeutics shares trade on Nasdaq in U.S. dollars. The company remains a small-cap biotech name, and the stock's next major move typically depends on pipeline disclosure, financing terms or broader biotech sentiment.

Fact box

• Company: Monopar Therapeutics Inc.
• ISIN: US6093601054
• Ticker: MNPR
• Exchange: Nasdaq
• Price (as of July 7, 2026, 5:01 p.m. ET): not available in the search results
• Sector / Industry: Health Care / Biotechnology
• Index membership: not verified
• Next earnings date: not yet officially scheduled

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.